Glenmark Pharma's arm receives USFDA’s approval for Fulvestrant Injection

23 Aug 2019

Glenmark Pharmaceuticals’ subsidiary -- Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (USFDA) for Fulvestrant Injection, 250 mg/5 mL (50 mg/mL), a generic version of Faslodex Injection, 250 mg/5 mL (50 mg/mL), of AstraZeneca Pharmaceuticals LP. 

According to IQVIA sales data for the 12 month period ending June 2019, the Faslodex Injection, 250 mg/5 mL (50 mg/mL) market achieved annual sales of approximately $549.9 million.

Glenmark Pharmaceuticals is a global pharmaceutical company. The company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW).

Related Glenmark Pharmaceuticals Ltd. Links:

Glenmark Pharma Share Price

622.75 -2.90 (-0.46%) May 11, 15:17
1 Year Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 708.00
Dr. Reddys Lab 5296.50
Lupin 1197.05
Piramal Enterprises 1693.45
Cadila Healthcare 628.55
View more..
Sensex vs Glenmark Pharma
Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323

Callback